Details

Vpliv genetske variabilnosti v vnetnih poteh na zdravljenje z obsevanjem pri duktalnem karcinomu in situ
ID Jeram, Ema (Author), ID Trebušak Podkrajšek, Katarina (Mentor) More about this mentor... This link opens in a new window, ID Goričar, Katja (Comentor)

.pdfPDF - Presentation file, Download (2,05 MB)
MD5: C82B35EBE78FE4C440BA92755294BBE6

Abstract
Duktalni karcinom in situ (DCIS) je neinvazivna oblika raka dojk. Najpogosteje ga zdravimo z operacijo in dopolnilnim obsevanjem. Obsevanje sicer preprečuje lokalne ponovitve bolezni, a lahko povzroči akutne in pozne neželene učinke. Pri tem igra pomembno vlogo vnetni odgovor, saj obsevanje sproži nastanek reaktivnih kisikovih zvrsti, ki poškodujejo celične makromolekule ter vplivajo na številne celične procese, povezane s celičnim stresnim odzivom. Bolnice se na zdravljenje z obsevanjem odzivajo različno, na kar bi lahko vplivala tudi genetska variabilnost v vnetnih poteh. Z magistrsko nalogo smo želeli preveriti, ali je genetska variabilnost v vnetnih poteh povezana s pojavom akutnih in poznih neželenih učinkov obsevanja pri bolnicah z DCIS. V prospektivno longitudinalno raziskavo je bilo vključenih 199 bolnic z DCIS, ki so se zdravile na Onkološkem inštitutu v Ljubljani. Neželene učinke zdravljenja z obsevanjem smo spremljali na koži in srcu takoj po obsevanju ter eno leto kasneje. Iz izolirane DNA iz vzorcev polne krvi bolnic smo s kompetitivno alelno specifično verižno reakcijo s polimerazo določili prisotnost polimorfizmov v ključnih genih, povezanih z vnetnim odzivom (CARD8, NLRP3, IL1B, MIR146A, IL6, IL6R, TNF). S pomočjo bioinformatskih orodij smo preverili, v katerih bioloških procesih sodelujejo izbrani geni in kako interagirajo med sabo. Na podlagi rezultatov smo ugotovili, da polimorfizma IL6R rs2228145 in IL6 rs1800795 vplivata na pojav akutnih neželenih učinkov na koži po obsevanju. Opazili smo tudi povezavo med polimorfizmoma rs1143623 in rs16944 v genu IL1B ter verjetnostjo za pozne neželene učinke. Poleg tega smo opazili povezavo med polimorfizmoma IL1B rs1071676 in MIR146A rs2910164 ter pojavnostjo akutnih neželenih učinkov na srcu. Naše ugotovitve podpirajo hipotezo, da genetska variabilnost v vnetnih poteh pomembno vpliva na tveganje za pojav neželenih učinkov terapije z obsevanjem. Ti rezultati bi lahko doprinesli k personalizaciji zdravljenja DCIS v prihodnosti. Za dosego tega cilja pa je potrebno izvesti nadaljnje raziskave, s katerimi bi potrdili povezavo med genetskimi dejavniki in odzivom na zdravljenje.

Language:Slovenian
Keywords:duktalni karcinom in situ, obsevanje, genetska variabilnost, vnetje
Work type:Master's thesis/paper
Typology:2.09 - Master's Thesis
Organization:FFA - Faculty of Pharmacy
Publisher:[E. Jeram]
Year:2026
PID:20.500.12556/RUL-188910 This link opens in a new window
UDC:575.22:616-006(043.2)
COBISS.SI-ID:293801987 This link opens in a new window
Publication date in RUL:30.09.2026
Views:167
Downloads:65
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Secondary language

Language:English
Title:The impact of genetic variability in inflammatory pathways on response to radiotherapy in ductal carcinoma in situ
Abstract:
Ductal carcinoma in situ (DCIS) is a non-invasive form of breast cancer. It is usually treated with surgery and adjuvant radiotherapy. While radiotherapy helps to prevent local recurrence of the disease, it can also cause acute and late adverse effects. The inflammatory response plays an important role in this process, as irradiation induces the formation of reactive oxygen species, which damage cellular macromolecules and affect numerous cellular processes associated with the cellular stress response. Patients respond differently to radiotherapy, which may also be influenced by genetic variability in inflammatory pathways. The aim of this master’s thesis was to investigate whether genetic variability in inflammatory pathways is associated with the occurrence of acute and late adverse effects of radiotherapy in patients with DCIS. The prospective longitudinal study included 199 patients with DCIS who were treated at the Oncology Institute in Ljubljana. Skin and cardiac adverse effects of radiotherapy were evaluated immediately after treatment and one year later. DNA isolated from patients’ whole blood samples was analyzed using competitive allele-specific PCR to determine the presence of polymorphisms in key genes related to the inflammatory response (CARD8, NLRP3, IL1B, MIR146A, IL6, IL6R, TNF). Bioinformatic tools were used to examine the biological processes in which these genes are involved and how they interact with each other. Based on the results we found that the polymorphisms IL6R rs2228145 and IL6 rs1800795 influence the occurrence of acute skin adverse effects after radiotherapy. We also observed an association between polymorphisms rs1143623 and rs16944 in the IL1B gene and the likelihood of late adverse effects. In addition, we observed an association between IL1B rs1071676 and MIR146A rs2910164 polymorphisms and the occurrence of acute cardiac adverse effects. These findings support the hypothesis that genetic variability in inflammatory pathways significantly influences the risk of side effects from radiotherapy. These findings might contribute to the personalization of DCIS treatment in the future. To achieve this goal, further studies are needed to confirm the relationship between genetic factors and treatment response.

Keywords:ductal carcinoma in situ, radiotherapy, genetic variability, inflammation

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back